DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Albiges L, Tannir NM, Burotto M. et al.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
ESMO Open 2020;
5: e001079
DOI: 10.1136/esmoopen-2020-001079. (PMID: 33246931)
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.